Johnson & Johnson has completed its $1 billion all-cash acquisition of Firefly Bio, a biotechnology company developing the proprietary Firelink degrader antibody conjugate (DAC) platform, further strengthening its oncology portfolio.
The acquisition strengthens Johnson & Johnson’s capabilities in next-generation antibody engineering and supports its strategy to develop targeted therapies for some of the most prevalent and difficult-to-treat solid tumours, including KRAS-driven cancers, where patients continue to face significant unmet need.
Firefly Bio’s Firelink DAC platform is designed to deliver highly selective protein degraders directly to cancer cells, enabling targeted activity while preserving healthy tissue—a key limitation of many current treatment approaches.
“The completion of this acquisition marks an important step in advancing new approaches to better address difficult-to-treat solid tumours,” said John Reed, executive vice president, Innovative Medicine, Research & Development, Johnson & Johnson.
“By bringing together Firefly Bio’s differentiated technology with our deep expertise in oncology and antibody engineering, we are well positioned to accelerate the development of more precise and effective therapies,” he added.
Johnson & Johnson said the deal will be treated as an asset acquisition, resulting in an approximately $1 billion in-process research and development (IPR&D) charge in the third quarter of 2026. The company also expects the transaction to reduce adjusted operational earnings per share and adjusted earnings per share by about $0.46 in 2026 and $0.08 in 2027.
